Cytokinetics, Incorporated Reports Second Quarter 2011 Financial Results

Cytokinetics reported total research and development revenues of $1.1 million for the second quarter of 2011. The company recently advanced their drug development pipeline with the initiation of dosing in a second Phase II trial of their skeletal muscle activator, CK-2017357, in patients with ALS. Initiation of a Phase IIb clinical trial of CK-2017357 in ALS patients is expected for 2012.

Click here to read more.

Share this: